Subscribe To
Pharvaris to present in upcoming march investor conferences
ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor ...
March 2, 2023, 6:50 am
Ocugen, inc. announces submission of investigational new drug application with u.s. fda to initiate a phase 1 clinical trial evaluating ocu200 for the treatment of diabetic macular edema
MALVERN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on d...
February 27, 2023, 10:57 pm
Nu holdings ltd. (nu) q4 2022 earnings call transcript
Nu Holdings Ltd. (NYSE:NU ) Q4 2022 Results Conference Call February 14, 2023 5:00 PM ET Company Participants Jorg Friedemann - Investor Relations Dav...
February 14, 2023, 9:05 pm
Diagnos and ets to present ground-breaking research on mass screening for macular edema at arvo 2023
BROSSARD, Quebec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) ...
February 14, 2023, 10:37 am
Pharvaris to present at svb securities global biopharma conference
ZUG, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor a...
February 8, 2023, 6:50 am
Glenmark pharmaceuticals launches congestive heart failure injection in united states
Bumetanide is used to reduce extra fluid in the body (edema) caused by conditions such as congestive heart failure, liver disease, and kidney disease....
January 10, 2023, 7:29 am
What is pulmonary edema?
One of the most common causes of pulmonary edema is congestive heart failure, in which the heart cannot...
January 9, 2023, 9:29 am
Heart failure
Find out more. edema often occurs as the result of congestive heart failure. It can also be the result ...
December 29, 2022, 12:44 am
Astria therapeutics: tailwinds building with novel treatment paradigm
ATXS has broken out from a 37-week price reversal. Hereditary angioedema is a rare genetic disorder cha...
December 24, 2022, 12:38 am
Biocryst pharmaceuticals: more aggressive growth for orladeyo
As a stellar drug for hereditary angioedema, BioCryst Pharmaceuticals' Orladeyo is enjoying strong sales reactions in its second year of launch. Coupl...
December 20, 2022, 4:47 pm
Tactile systems: lymphedema, airway clearance markets attractive
Tactile Systems Technology, Inc. continues to grow its top line hastily each quarter, which demonstrates it is capturing additional market share. Airw...
December 9, 2022, 6:54 pm
Pharvaris shares soar on positive top-line phase 2 data from rapide-1 study as it releases 3q results
Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angio...
December 8, 2022, 11:34 am
Why is pharvaris (phvs) stock up 62% today?
Pharvaris (NASDAQ: PHVS ) stock is heading higher on Thursday following the release of positive results from a Phase 2 clinical study. That clinical t...
December 8, 2022, 10:37 am
Investing ideas for 2023 according to experts
As we head towards the end of 2022, one thing is certain – uncertainty. With so much ambiguity, it’s difficult to decide where to invest your mone...
December 8, 2022, 3:02 am
Investing ideas for 2023 according to experts
As we head towards the end of 2022, one thing is certain – uncertainty. With so much ambiguity, it’s difficult to decide where to invest your mone...
December 7, 2022, 1:13 pm
Nu holdings ltd. (nu) q3 2022 earnings call transcript
Nu Holdings Ltd. (NYSE:NU ) Q3 2022 Results Conference Call November 14, 2022 5:00 PM ET Company Participants Jorg Friedemann - IR Officer David Véle...
November 14, 2022, 10:37 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...
November 12, 2022, 9:30 pm